Efavirenz in the management of HIV infection

International Journal of Clinical Practice

Volumn 53, Issue 1, 1999, Pages 60-64

  Gazzard, B G ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; INDINAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RIFAMPICIN; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ADMINISTRATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG PROTEIN BINDING; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RASH; REVIEW; VERTIGO; VIRUS INHIBITION;

ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; OXAZINES; TREATMENT OUTCOME;

EID: 0033047411     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Miller V. Staszewski S, Boucher CAB, Phair JP. Clinical experience with non-nucleoside reverse transcriptase inhibitors. AIDS 1997; 11(Suppl A): S157-S164.
2. Hizi A, Tal R. Shaharabany M et al. Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and type 2 by non-sucleoside inhibitors. Antimicrob Agents Chemother 1993; 37: 1037-1042.
3. Drosopoulos WC, Rezende LF, Wainberg MA, Prasad VR. Virtues of being faithful: can we limit the genetic variation in human immunodeficiency virus? J Mol Med 1998; 76: 604-612.
4. Perelson AS, Neumann AU, Markowitz M et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271: 1582-1586.
5. Chow YK, Hirsch MS, Merrill DP et al. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature 1993; 361: 650-654.
6. Hammer SM, Kessler HA, Saag MS. Issues in combination antiretroviral therapy: a review. J AIDS Hum Retrovirol 1994; 7(Suppl 2): S24-S35.
7. Johnson VA. Combination therapy: more effective control of HIV type 1? AIDS Res Hum Retroviruses 1994; 10: 907-912.
8. Richman DD, Havlir D Corbeil J et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994; 68: 1660-1666.
9. Havlir DV, Eastman S, Gamst A, Richman DD. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol 1996; 70: 7894-7899.
10. Demeter LM, Meehan PM, Morse G et al. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanoise and delvirdine. J AIDS Hum Retrovirol 1997; 14: 136-144.
11. Bacheler L, Weislow O, Snyder S et al. Virological resistance to efavirenz. Presented at the 12th World AIDS conference, Geneva, Switzerland June 28-July 3, 1998. Poster 41213.
12. De Clercq E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res 1998; 38: 153-179.
13. Miller V, de Bethune MP, Kober A et al. Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the non-nucleoside reverse transcriptase inhibitor loviride. Antimicrob Agents Chemother 1998; 42: 3123-3129.
14. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee. Lancet 1994; 343: 871-881.
15. Katlama C, Havlir D. Newer nucleosides: lamivudine and stavudine. AIDS 1996; 10(suppl A): S135-S143.
16. Carr A, Cooper DA. HIV protease inhibitors. AIDS 1996; 10(suppl A): S151-157.
17. Darbyshire J. Perspectives in drug therapy of HIV infection. Drugs 1995; 49(suppl 1): 1-3.
18. Moyle GJ, Gazzard BG, Peto T. Surrogate markers now provide physicians with the best means to manage antiretroviral therapy: the case for. Genitourin Med 1997; 73: 216-220.
19. Riddler SA, Mellors JW. HIV-1 viral load and clinical outcome: review of recent studies. AIDS 1997; 11(suppl A): S141-S148.
20. Daniels MJ, Hughes MD. Meta-analysis for the evaluation of potential surrogate markers. Stat Med 1997; 16: 1965-1982.
21. Mildvan D, Landay A, De Gruttola et al. An approach to the validation of markers for use in AIDS clinical trials. Clin Infect Dis 1997; 24: 764-774.
22. Data on file.
23. Data on file.
24. Kempf DJ, Rode RA, Xu Y el al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998; 12: F9-F14.
25. Mellors JW, Kingsley LA, Rinaldo CR Jr et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122: 573-579.
26. Havlir D, Hicks C, Kahn J et al. Durability of antiviral activity of efavirenz (EFV, DMP 266) in combination with indinavir (IDV) (DMP 266-003, Cohort IV). Presented at the 38th ICAAC, San Diego, September 24-27, 1998. Poster 1-104.
27. Mayers D, Jemesk J, Eyster E et al. A double-blind, placebo-controlled study to assess the safety, tolerability and antiretroviral activity of efavirenz (EFV, SUSTIVATM, DMP266) in combination with open-label zidovudine (ZDV) and lamivudine (3TC) in HIV-1 infected patients (DMP 266-004).
28. Presented at the 12th World AIDS Conference, Geneva, Switzerland June 28-July 3, 1998. Poster 22340.
29. Gallant J, Seekins D, Hicks C el al. A phase II, double-blind, placebo-controlled, dose ranging study to assess the antiretroviral activity and safety of efavirenz (EFV, SUSTIVATM, DMP266) in combination with open-label zidovudine (ZDV) with lamivudine (3TC) at 48 weeks (DMP 266-005). Presented at the 38th ICAAC, San Diego, September 24-27, 1998. Poster 1-245.
30. AIDS Clinical Trials Group. Comparison of the virologic efficacy of nelfinavir (NFV) and/or efavirenz (EFV) with one of two new nucleoside analogues in nucleoside experienced subjects. Presented at the 12th World AIDS Conference, Geneva, Switzerland June 28-July 3, 1998. Poster ACTG 364.
31. Morales-Ramirez J, Tashima K, Hardy D et al. A phase III, multi-center, randomized, open-label study to compare the antiretroviral activity and tolerability of efavirenz (EFV) + indinavir (IDV), versus EFV + zidovudine (ZDV) + lamivudine (3TC), versus IDV+ZDV+3TC at 36 weeks (DMP 266-006). Presented at the 38th ICAAC, San Diego September 24-27, 1998. Poster 1-103.
32. Montaner JSG, Reiss P. Cooper D. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS trail. JAMA 1998; 279: 930-937.
33. Data on file.
34. Data on file.
35. Data on file.
36. Data on file.
37. Data on file.
38. Data on file.
39. Benedek JH, Joshi A. Fiske WD et al Pharmacokinetic interaction between efavirenz (EFV) and rifampin (RIF) in healthy volunteers. Presented at the 12th World Conference, Geneva, Switzerland, June 28-July 3, 1998. Poster 42280.
40. Detels R, Munoz A, McFArlane G et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multi-center AIDS cohort study investigators. JAMA 1998; 280: 1497-1503.
41. Report of the NIH panel to define principles of therapy of HIV infection. Ann Intern Med 1998; 128: 1057-1078.
42. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Ann Intern Med 1998; 128: 1079-1099.
43. Gazzard BG, Moyle GJ, Weber J et al. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997; 349: 1086-1092.
44. Gazzard B, Moyle G, on behalf of the British HIV Association Guidelines Writing Committee. 1998 revision to the British HIV Association guidelines for antiretroviral treatment for HIV seropositive individuals. Lancet 1998; 352: 314-316.
45. Pakyz A, Israel D. Overview of protease inhibitors. J Am Pharm Assoc 1997; NS37: 543-551.
46. Carr A. Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
47. Lo JC, Mulligan K, Tai VW et al. 'Buffalo hump' in men with HIV-1 infection. Lancet 1998; 351: 867-870.
48. Miller KD, Jones E, Yanovski JA et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351: 871-875.
49. Shaw AJ, McLean KA, Evans BA. Disorders of fat distribution in HIV infection. Int J STD AIDS 1998; 9: 595-599.
50. Moyle GJ, Youle M, Higgs C et al. Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus. J Clin Pharmacol 1998; 38: 736-743.
51. Singh N, Squier C, Silvek C et al. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care 1996; 8: 261-269.
52. Data on file.